Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma

Severe eosinophilic asthma (SEA) is associated with high peripheral blood and airway eosinophilia, recurrent disease exacerbations and severe airflow limitation. Eosinophilic inflammation is also responsible for small airway disease (SAD) development. SEA patients experience poor disease control and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Angelantonio Maglio, Carolina Vitale, Simona Pellegrino, Cecilia Calabrese, Maria D’Amato, Antonio Molino, Corrado Pelaia, Massimo Triggiani, Girolamo Pelaia, Cristiana Stellato, Alessandro Vatrella
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
severe asthma
mepolizumab
eosinophils
lung function
FEF25-75
ACT
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/75cb49082e334b6f9ca52940d0d6f952
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/75cb49082e334b6f9ca52940d0d6f952

Ejemplares similares